Candidate genes for antidepressant response to selective serotonin reuptake inhibitors
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) can safely and successfully treat major depression, although a substantial number of patients benefit only partially or not at all from treatment. Genetic polymorphisms may play a major role in determining the response to SSRI treatment. Nonetheless, it is likely that efficacy is determined by multiple genes, with individual genetic polymorphisms having a limited effect size. Initial studies have identified the promoter polymorphism in the gene coding for the serotonin reuptake transporter as moderating efficacy for several SSRIs. The goal of this review is to suggest additional plausible polymorphisms that may be involved in antidepressant efficacy. These include genes affecting intracellular transductional cascades; neuronal growth factors; stress-related hormones, such as corticotropin-releasing hormone and glucocorticoid receptors; ion channels and synaptic efficacy; and adaptations of monoaminergic pathways. Association analyses to examine these candidate genes may facilitate identification of patients for targeted alternative therapies. Determining which genes are involved may also assist in identifying future, novel treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Botstein, D., & Risch, N. (2003) · Nature Genetics · doi:10.1038/ng1090 · Cited by 1,503 · cited 2×
“However, given that there may be over 30 000 genes and several million polymorphisms in humans (Sachidanandam et al 2001; Venter et al 2001; Botstein and Risch 2003), densely screening the genome may require testing up to a million polymorphisms per individual (Botstein and Risch 2003).”
BackgroundGold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 2×
“Other potential downstream effector molecules for BDNF that may enhance neuronal survival, augment neuroplasticity, or decrease apoptosis include Bcl-2 and glycogen synthase kinase 3 (Manji et al 2001; Gould and Manji 2002; Manji and Chen 2002).”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“There is also the ever-escalating problem of placebo response rates in clinical trials (Walsh et al 2002).”
BackgroundA functional polymorphism in the monoamine oxidase A gene promoter
Sabol, S. Z., Hu, S., & Hamer, D. (1998) · Human Genetics · doi:10.1007/s004390050816 · Cited by 1,079
Candidate-gene approaches for studying complex genetic traits: practical considerations
Tabor, H. K., Risch, N. J., & Myers, R. M. (2002) · Nature Reviews Genetics · doi:10.1038/nrg796 · Cited by 1,076
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Neuroimaging studies of mood disorder effects on the brain
Sheline, Y. I. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00347-0 · Cited by 660
Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07397.2001 · Cited by 509 · cited 1×
“Conversely, increased CREB expression in the nucleus accumbens may adversely affect motivated behavior (Pliakas et al 2001; Newton et al 2002).”
BackgroundFunctional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Thase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331
Newton, S. S., Thome, J., Wallace, T. L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E. J., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10883.2002 · Cited by 313
Nicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275 · cited 1×
“In fact, antagonism at 5-HT2a can augment the efficacy of SSRIs (Marek et al 2003), and response to SSRI treatment has been associated with normalization of 5-HT2a receptor binding (Messa et al 2003).”
BackgroundHuizenga, N. A. T. M. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.1.144 · Cited by 265
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cytokines, stress, and depressive illness
Anisman, H., & Merali, Z. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00009-0 · Cited by 225
Mineralocorticoid Receptor Function in Major Depression
Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J., & Akil, H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.24 · Cited by 204 · cited 1×
“Of note, mineralocorticoid receptor (MR) gene expression is also affected by chronic antidepressant treatment in rats (Brady et al 1991), and MR function has also been linked to the pathophysiology of depression (Young et al 2003).”
BackgroundHawi, Z., Dring, M., Kirley, A., Foley, D., Kent, L., Craddock, N., Asherson, P., Curran, S., Gould, A., Richards, S., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001048 · Cited by 175 · cited 1×
“Polymorphisms in the gene for 5-HT1b, including a common A(-161)T SNP in the promoter region, have been preliminarily associated with several psychiatric phenotypes, including suicide (Hawi et al 2002; Sanders et al 2002).”
BackgroundGomez, L. L., Alam, S., Smith, K. E., Horne, E., & Dell'Acqua, M. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-07027.2002 · Cited by 170 · cited 1×
“Conversely, the activity of AKAP79/150 is regulated by PKC and calmodulin (Gomez et al 2002).”
BackgroundAltered Stress-Induced Anxiety in Adenylyl Cyclase Type VIII-Deficient Mice
Schaefer, M. L., Wong, S. T., Wozniak, D. F., Muglia, L. M., Liauw, J. A., Zhuo, M., Nardi, A., Hartman, R. E., Vogt, S. K., Luedke, C. E., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-13-04809.2000 · Cited by 152
Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor
Laplante, P., Diorio, J., & Meaney, M. J. (2002) · Developmental Brain Research · doi:10.1016/s0165-3806(02)00550-3 · Cited by 135
cAMP-dependent protein kinase activity in major depression
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.8.1037 · Cited by 105 · cited 1×
“Abnormalities in PKA/CREB signaling have been associated with mood disorders (Shelton et al 1996; Rahman et al 1997; Chang et al 2003; Kohen et al 2003).”
BackgroundChang, B. H., Mukherji, S., & Soderling, T. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00520-0 · Cited by 95 · cited 1×
“Polymorphisms in some CAMKII isoforms have been demonstrated (Gloyn et al 2002), and both the α and β isoforms for CAMKII are expressed in the brain (Chang et al 2001).”
BackgroundBehavior Genetics of Drug Sensitization
Phillips, T. J. (1997) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v11.i1.20 · Cited by 54 · cited 2×
“Candidate genes may be selected from these chromosomal regions; a strategy that is being employed for genes affecting sensitivity to drugs of abuse (Buck 1995; Phillips 1997; Fehr et al 2002).”
Background
Cited by
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review
Webb, L. M., Phillips, K. E., Ho, M. C., Veldic, M., & Blacker, C. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030826 · Cited by 84
“5HT1B has been associated with serotonin synthesis and influences behavior and anxiety in animal models [76].”
BackgroundHoyo-Becerra, C., Huebener, A., Trippler, M., Lutterbeck, M., Liu, Z. J., Truebner, K., Bajanowski, T., Gerken, G., Hermann, D. M., & Schlaak, J. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083149 · Cited by 49
Central nervous system-acting drugs influencing hypothalamic-pituitary-adrenal axis function
Locatelli, V., Bresciani, E., Tamiazzo, L., & Torsello, A. (2010) · Endocrine development · doi:10.1159/000262533 · Cited by 48
Lenze, E. J., Dixon, D., Nowotny, P., Lotrich, F. E., Doré, P. M., Pollock, B. G., Hinrichs, A. L., & Butters, M. A. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000351 · Cited by 23
“SSRIs affect cortical and subcortical regions involved in attention and other aspects of neurocognition (Lotrich & Pollock, 2005 ; Smith et al. 2011).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Lotrich, F. E., & Pollock, B. G.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2005
- Volume
- 1
- Issue
- 1
- Pages
- 17-35
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W1964888885
- Cited by
- 33
- References
- 25
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.